22.05.2008 – 20:41
Active Ingredients & Specialty Chemicals Division of Atrium Innovations Strikes out on its own and Becomes UNIPEX Group
Quebec City, Canada (ots/PRNewswire)
- UNIPEX Group Finalizes Acquisition of Atrium Innovations' Active Ingredients & Specialty Chemicals Division
UNIPEX Group is pleased to announce the successful completion of its acquisition of the Active Ingredients & Specialty Chemicals Division of Atrium Innovations Inc., with the new group being held by its management team and the AXA Private Equity investment fund. UNIPEX Group operational headquarters will remain in Quebec City with the current team under the leadership of Charles Boulanger, President and CEO.
UNIPEX Group is a global firm specializing in the manufacture and distribution of active ingredients, specialty and base chemicals for the cosmetic, pharmaceutical, specialty and industrial chemical and nutrition industries. It is currently present in over 50 countries and recognized as a leader in its main areas of activity. In 2007 the firm achieved sales of over $220 million US, maintaining sustained growth in Europe, North America and Asia. UNIPEX Group will continue to operate the firms acquired in this transaction under three trade-specific identities:
@@start.t1@@ - UNIPEX Innovations, which will include the global operations for
development, manufacture and marketing of proprietary active
ingredients targeted at the cosmetic industry;
- UNIPEX Solutions France, which will incorporate the distribution
companies for active ingredients, specialty chemicals and services in
- UNIPEX Solutions Canada, which will encompass the distribution
activities for active ingredients, specialty chemicals and services
"Melding the various firms we have acquired within UNIPEX Group will enable us to consolidate our operations and provide the strategic advantage of a comprehensive solution ranging from active ingredient research and development to manufacturing and marketing, distribution, logistics, and cosmetovigilance services; this grouping under a single brand will help create a more uniform relationship with our clients and promote stronger synergy among our teams. Overall, we will be able to further develop our expertise, increase our ability to innovate, and thus realize the full potential of our strategic plan," said President and CEO Charles Boulanger.
About UNIPEX Group
UNIPEX Group specializes in the development, manufacture, and distribution of active ingredients and specialty chemicals for world-class producers in the cosmetics, pharmaceutical, specialty chemical, consumer and nutrition industries. UNIPEX Group is also active in the areas of cosmetovigilance and consumer testing through its cosmetics evaluation services. Its distribution and marketing network serves more than 50 countries in North America, Europe, and Asia and boasts over 150 employees in 5 offices in North America and Europe. Additional information regarding Groupe UNIPEX is available at http://www.unipex.com.
About AXA Private Equity
AXA Private Equity - an AXA Investment Managers company - is one of the world's leading private equity firms. AXA Private Equity offers investors a broad selection of high performance funds for every market segment: Buyout, Expansion Capital, Venture Capital, Co-investments, Infrastructure, Mezzanine, Primary, Early Secondary and Secondary Funds of Funds. The firm manages and/or advises on more than US$22 billion of funds on behalf of leading international investors. Backed by its offices in Paris, Frankfurt, London, Milan, New York and Singapore, AXA Private Equity stands out from the competition through the expertise of its teams and its broad international presence. The firm maintains a constant focus on transparency, performance and sustainable profitability. Additional information about AXA Private Equity is available on its Web site at http://www.axaprivateequity.com.
For further information:
Investor and media relations:
President and CEO,
AXA Private Equity:
ots Originaltext: Unipex Group
Im Internet recherchierbar: http://www.presseportal.ch
For further information: Investor and media relations: Charles
Boulanger, President and CEO, +1-418-652-1116, email@example.com;
AXA Private Equity: Catherine Gros, +33-1-53-70-74-70,
Catherine.firstname.lastname@example.org; Flore Larger, email@example.com